Combined with the good activity of the EGFR inhibitor SMUZ106 against TMZ-resistant cells presented in this study, it can be suggested that EGFR inhibitors have promising potential for the treatment of GBM resistance in the future. This evidence concerns the gene EGFR and glioblastoma.